“…CAFs are most commonly identified by their expression of fibroblast activation protein (FAP) and alpha smooth muscle actin (∂-SMA), however, additional markers including platelet derived growth factor receptor b (PDGFRB), fibroblast specific protein (FSP) and vimentin (VIM), all of whose expression in tumor stroma have, like ∂-SMA, been linked to poor outcome of many cancers, can also be expressed in CAFs (Jacob et al, 2012 ; Folgueira et al, 2013 ; Paulsson and Micke, 2014 ; Han et al, 2015 ; Peiris-Pagès et al, 2015 ; Corvigno et al, 2016 ; Gascard and Tlsty, 2016 ; Kuzet and Gaggioli, 2016 ; Hammer et al, 2017 ; Tao et al, 2017 ; von Ahrens et al, 2017 ). The roles of CAFs as promoters of tumor initiation, progression, epithelial to mesenchymal transition, stemness, tumor invasion, angiogenesis, metastasis and drug resistance are well established (Kalluri and Zeisberg, 2006 ; Shekhar et al, 2007 ; Straussman et al, 2012 ) Experimentally, CAFs exhibit activity in all Hallmarks of Cancer categories (Salo et al, 2014 ; Tommelein et al, 2015 ; Attieh and Vignjevic, 2016 ; Mezawa and Orimo, 2016 ).…”